Plasma PCSK9 Levels Are Elevated with Acute Myocardial Infarction in Two Independent Retrospective Angiographic Studies

• Published in: PloS one Vol. 9; no. 9; p. e106294
• Main Authors: Almontashiri, Naif A. M., Vilmundarson, Ragnar O., Ghasemzadeh, Nima, Dandona, Sonny, Roberts, Robert, Quyyumi, Arshed A., Chen, Hsiao-Huei, Stewart, Alexandre F. R.
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 02.09.2014; Public Library of Science (PLoS)
• Subjects: Anticholesteremic agents; Arteriosclerosis; Atherosclerosis; Biochemistry; Biological Specimen Banks; Biology and Life Sciences; Blood cholesterol; Canada; Cardiology; Cardiovascular disease; Case-Control Studies; Cholesterol; Coronary Angiography; Coronary artery; Coronary Artery Disease - blood; Coronary vessels; Diabetes; Drugs; Enzyme-linked immunosorbent assay; Female; Genetics; Genomics; Health risk assessment; Heart; Heart attack; Heart attacks; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Immunology; Kexin; Linear Models; Logistic Models; Low density lipoprotein; Low density lipoprotein receptors; Low density lipoproteins; Male; Medical imaging; Medicine; Middle Aged; Mutation; Myocardial infarction; Myocardial Infarction - blood; Myocardial Infarction - drug therapy; Proprotein Convertase 9; Proprotein convertases; Proprotein Convertases - blood; Receptor density; Retrospective Studies; Secretion; Serine Endopeptidases - blood; Stenosis; Studies; Subtilisin; Canada; Montreal Quebec Canada; Ottawa Ontario Canada

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a circulating protein that promotes degradation of the low density lipoprotein (LDL) receptor. Mutations that block PCSK9 secretion reduce LDL-cholesterol and the incidence of myocardial infarction (MI). However, it remains unclear whether ele...